Skripsi
PERBEDAAN FUNGSI KOGNITIF BERDASARKAN FAKTOR KLINIKOPATOLOGIS PADA PASIEN KANKER PAYUDARA YANG MENJALANI KEMOTERAPI DI RS MOHAMMAD HOESIN
Chemotherapy is the main treatment for breast cancer; however, it may cause cognitive impairment, known as chemobrain, which is characterized by a decline in memory, attention, reasoning, concentration, processing speed, executive function, and visual ability. Clinicopathological factors such as age, education, marital status, cancer stage, type and number of chemotherapy cycles are believed to play a role in cognitive decline. This study aims to analyze the differences in cognitive function based on clinicopathological factors. Using an observational analytical design with a cross-sectional approach, the study included 110 breast cancer patients undergoing chemotherapy at Mohammad Hoesin Hospital, Palembang, from July to September 2025. Data were collected using interviews with the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-COG) questionnaire. Most respondents were 41–60 years old (96.4%), had a high school or vocational education (32.7%), were married (99.1%), and were diagnosed with stage III cancer (74.5%). The most frequently used chemotherapy regimen was the Docetaxel–Cyclophosphamide–Doxorubicin (TAC) combination, with the majority receiving ≥4 cycles (52.7%). Significant differences were found between the number of chemotherapy cycles and cognitive function, as seen in the Perceived Cognitive Impairment (PCI) subscale (p=0.011) and the total FACT-Cog score (p=0.032). However, no significant differences were found between cognitive function and factors such as age, education level, marital status, cancer stage, or type of chemotherapy (p>0.05). The number of chemotherapy cycles was significantly associated with a decline in cognitive function in breast cancer patients, while other clinical-pathological factors did not show any significant differences.